Mirum Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
Mailing Address 989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
Phone 650-667-4085
Fiscal Year End 1231
EIN 831281555
Financial Overview
FY2024
-$135.66M
Net Income
$248.67M
Stockholders' Equity
$286.33M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | January 27, 2026 | View on SEC |
Material Events
8-K Acquisition January 26, 2026
High Impact
- Dramatically expands Mirum's drug development pipeline and strengthens its standing in rare disease therapeutics.
- Acquisition of Bluejay's promising pipeline, including a key lead asset, aligns well with Mirum's established expertise in rare liver diseases.
Insider Trading
STRONG SELL 8 insiders
21 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.